Skip to main content
IlluminaLinkedIn

Illumina expands MRD research ecosystem with NovaSeq X and DRAGEN ctDNA monitoring.

Source: Autobound Signal API · 107 signals tracked for Illumina · updated

Get Illumina's live signals in Claude or ChatGPT, or by API

AskWhat changed at Illumina this week? Use Autobound signals for illumina.com.

Source

LinkedInNov 9, 2026
likes
204
comments
3

Post

Researchers are pushing the boundaries of molecular residual disease (MRD) research. Today, we're expanding the Illumina MRD research ecosystem with Illumina duplex sequencing technology, designed to support ultra-sensitive whole-genome ctDNA monitoring. Built on the foundation of Illumina WGS oncology research workflows, the new technology is designed to: 🔬 Detect ultra-low-frequency variants across the genome 🔬 Achieve Q65+ accuracy with NovaSeq™ X and DRAGEN™ informatics 🔬 Support sensitivity at 2.5 ppm 🔬 Enable longitudinal ctDNA monitoring with 10 ng cfDNA input Together with Illumina WGS Oncology Prep, researchers now have complementary whole-genome sequencing workflow options to support MRD research programs from tumor fingerprinting through ultra-sensitive monitoring. Learn more and register interest in early access: https://bit.ly/4iGvfh5

linkedin.com/posts/illumina_researchers-are-pushing-the-boundaries-of...Read the full source

Extracted by Autobound

From the Signal API record
Signal
LinkedIn

What this signalsCompany posts often show what the team is pushing right now.

More LinkedIn signals at other companies

The full record

From the Signal API record

Topics and mentions

Tags

  • General Counsel
  • Research & Development
  • Medical Research

Initiatives

  • expanding MRD research ecosystem
  • NovaSeq X ctDNA monitoring early access

Technologies named

  • DRAGENTM
  • NovaSeqTM X

Extraction

Detected
Nov 9, 2026
signal_type
linkedin-post-company
signal_subtype
linkedinPost

Use this data

Get every LinkedIn signal for Illumina and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Illumina this week?”

  2. Send it to your own tools

    The Signal API returns LinkedIn signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full linkedin-post-company record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/fb805e84-d85e-4a95-8e18-7ec520ed1239 returns this record as JSON. POST /v1/companies/enrich returns every signal for illumina.com.

{
  "signal_id": "fb805e84-d85e-4a95-8e18-7ec520ed1239",
  "signal_type": "linkedin-post-company",
  "signal_subtype": "linkedinPost",
  "detected_at": "2026-11-09T15:21:21.343+00:00",
  "company": {
    "name": "Illumina",
    "domain": "illumina.com"
  },
  "data": {
    "tags": [
      "General Counsel",
      "Research & Development",
      "Medical Research"
    ],
    "summary": "Illumina expands MRD research ecosystem with NovaSeq X and DRAGEN ctDNA monitoring.",
    "post_url": "https://www.linkedin.com/posts/illumina_researchers-are-pushing-the-boundaries-of-activity-7525578283816689664-dgVQ",
    "num_likes": 204,
    "post_text": "Researchers are pushing the boundaries of molecular residual disease (MRD) research. Today, we're expanding the Illumina MRD research ecosystem with Illumina duplex sequencing technology, designed to support ultra-sensitive whole-genome ctDNA monitoring.\n\nBuilt on the foundation of Illumina WGS oncology research workflows, the new technology is designed to: \n🔬 Detect ultra-low-frequency variants across the genome\u000b\n🔬 Achieve Q65+ accuracy with NovaSeq™ X and DRAGEN™ informatics\u000b\n🔬 Support sensitivity at 2.5 ppm\u000b\n🔬 Enable longitudinal ctDNA monitoring with 10 ng cfDNA input\n\nTogether with Illumina WGS Oncology Prep, researchers now have complementary whole-genome sequencing workflow options to support MRD research programs from tumor fingerprinting through ultra-sensitive monitoring. \n\nLearn more and register interest in early access: https://bit.ly/4iGvfh5",
    "initiatives": [
      {
        "topic": "expanding MRD research ecosystem",
        "urgency": 0.6
      },
      {
        "topic": "NovaSeq X ctDNA monitoring early access",
        "urgency": 0.5
      }
    ],
    "posted_date": "2026-11-09T15:21:21.343Z",
    "num_comments": 3,
    "technologies_mentioned": [
      {
        "name": "DRAGENTM",
        "status": "considering"
      },
      {
        "name": "NovaSeqTM X",
        "status": "considering"
      }
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.